Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.095
Neutral
RSI(14)
54.590
Neutral
STOCH(KDJ)(9,3,3)
43.023
Neutral
ATR(14)
0.623
High Vlolatility
CCI(14)
47.941
Neutral
Williams %R
41.887
Buy
TRIX(12,20)
0.692
Sell
StochRSI(14)
66.320
Buy
Search
Shattuck Labs Inc
STTKAdd to Watchlist
7.100USD
+0.030+0.42%
Close 07-31 16:00（ET）Quotes delayed by 15 min
536.63MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.42%
5 Days
-4.44%
1 Month
+0.71%
6 Months
+84.42%
Year to Date
+94.52%
1 Year
+869.95%
Key Figures
7.280Open
7.430High
256.00Volume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.00%Turnover Ratio
7.070Prev. Close
6.905Low
1.75KTurnover
LossP/E Static
5.60P/B
0.00%Div Yield TTM
-55.64%ROA
8.33052wk High
-0.00Volume Ratio
-75.41MNet Profit
75.58MShares
-0.5642EPS TTM
1.11Beta
-61.04%ROE
0.71252wk Low
7.43%Amplitude
100.00%Gross Margin
536.63MMarket Cap
-0.40Reward/Risk
5.86%Risk Rate
TradingKey Stock Score of Shattuck Labs Inc
Currency: USD Updated: 2026-07-31Key Insights
Shattuck Labs Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 89 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.83.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Shattuck Labs Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Shattuck Labs Inc Highlights
StrengthsRisks
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.00M.
Undervalued
The company’s latest PE is -12.53, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 50.41M shares, increasing 16.19% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 173.27K shares of this stock.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
15.833
Target Price
+123.95%
Upside Space
Shattuck Labs Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
10
analysts
Buy
Current Rating
15.833
Target Price
+123.95%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Shattuck Labs Inc
STTK
10
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
6.976
Buy
MA10
7.045
Buy
MA20
6.979
Buy
MA50
6.062
Buy
MA100
6.375
Buy
MA200
4.807
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Shattuck Labs Inc Info
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Ticker SymbolSTTK
CompanyShattuck Labs Inc
CEOSchreiber (Taylor)
Websitehttps://www.shattucklabs.com/
Shareholders
Related Instruments
+0.73%
+0.76%
-4.42%
+0.66%
+1.19%
0.00%
+1.72%
+0.79%
+0.47%
+0.72%
+4.88%
+0.94%
0.00%
+0.91%
+0.21%
+0.58%
0.00%
0.00%
0.00%
-0.50%Popular Instruments
53020.200
+642.200 (+1.23%)
28277.000
+116.100 (+0.41%)
7527.400
+52.300 (+0.70%)
14604.000
-145.000 (-0.98%)
62555.000
-297.000 (-0.47%)
6413.300
+47.900 (+0.75%)
78.192
-7.742 (-9.01%)
311.530
+2.620 (+0.85%)
199.330
-1.420 (-0.71%)
4063.420
+21.990 (+0.54%)
FAQs
What is the current price of Shattuck Labs Inc (STTK)?
The current price of Shattuck Labs Inc (STTK) is 7.07.
What is the symbol of Shattuck Labs Inc?
The ticker symbol of Shattuck Labs Inc is STTK.
What is the 52-week high of Shattuck Labs Inc?
The 52-week high of Shattuck Labs Inc is 8.33.
What is the 52-week low of Shattuck Labs Inc?
The 52-week low of Shattuck Labs Inc is 0.71.
What is the market capitalization of Shattuck Labs Inc?
The market capitalization of Shattuck Labs Inc is 638.93M.
Is Shattuck Labs Inc (STTK) currently rated as Buy, Hold, or Sell?
According to analysts, Shattuck Labs Inc (STTK) has an overall rating of Buy, with a price target of 15.83.
What is the Earnings Per Share (EPS TTM) of Shattuck Labs Inc (STTK)?
The Earnings Per Share (EPS TTM) of Shattuck Labs Inc (STTK) is -0.70.